Izvorni kod stranice Denosumab

{{Drugbox-lat
| IUPAC_name        = 
| image             = 
| width             = 
| alt               = 
| image2            = 
| width2            = 
| alt2              = 
| imagename         = 
| drug_name         = Denosumab
| caption           =

<!-- Clinical data -->
| tradename         = Prolia, Ranmark, Xgeva
| Drugs.com         = {{drugs.com-lat|monograph|Denosumab}}
| MedlinePlus       = 
| licence_EU        = 
| licence_US        = 
| DailyMedID        = 
| pregnancy_AU      = 
| pregnancy_US      = 
| pregnancy_category= 
| legal_AU          = 
| legal_CA          = 
| legal_UK          = 
| legal_US          = 
| legal_status      = 
| dependency_liability = 
| routes_of_administration = Subkutano

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 25,4 dana
| excretion         =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|}}
| CAS_number        = 615258-40-7
| CAS_supplemental  = 
| ATCvet            = 
| ATC_prefix        = M05
| ATC_suffix        = BX04
| ATC_supplemental  = 
| PubChem           = 
| PubChemSubstance  = 
| IUPHAR_ligand     = 
| DrugBank_Ref      = {{drugbankcite|correct|drugbank}}
| DrugBank          = DB06643
| ChemSpiderID_Ref  = {{chemspidercite|correct|chemspider}}
| ChemSpiderID      = 
| UNII_Ref          = {{fdacite|correct|FDA}}
| UNII              = 
| KEGG_Ref          = {{keggcite|correct|kegg}}
| KEGG              = 
| ChEBI_Ref         = {{ebicite|correct|EBI}}
| ChEBI             = 
| ChEMBL_Ref        = {{ebicite|correct|EBI}}
| ChEMBL            = 1237023
| synonyms          =

<!-- Chemical data -->
| C=6404 | H=9912 | N=1724 | O=2004 | S=50
| molecular_weight = 144.7
| smiles            = 
| StdInChI          = 
| StdInChIKey_Ref   = {{stdinchicite|correct|chemspider}}
| StdInChI_comment  = 
| StdInChIKey       = 
| StdStdInChI_Ref   = {{stdinchicite|correct|chemspider}}
| density           = 
| melting_point     =  
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| specific_rotation = 
| sec_combustion    = 
}}
[[File:Denosumab.jpg|thumb|Denosumab]]
'''Denosumab'''<ref>{{cite journal|last=Pageau|first=Steven C.|title=Denosumab|journal=MAbs|year=2009|volume=1|issue=3|pages=210–215|doi=10.4161/mabs.1.3.8592|url=http://www.landesbioscience.com/journals/17/article/8592/|pmid=20065634|pmc=2726593}}</ref> je ljudsko [[monoklonalno antitelo]] za tretman [[osteoporoza|ostioporoze]], gubitka koštane mase, koštanih metastaza, [[multipli mijelom|multiplog mijeloma]], i [[Tumor gigantskih ćelija kostiju|tumora gigantskih ćelija kostiju]].<ref name="pmid16495394">{{cite journal |doi=10.1056/NEJMoa044459 |title=Denosumab in Postmenopausal Women with Low Bone Mineral Density |year=2006 |last1=McClung |first1=Michael R. |last2=Lewiecki |first2=E. Michael |last3=Cohen |first3=Stanley B. |last4=Bolognese |first4=Michael A. |last5=Woodson |first5=Grattan C. |last6=Moffett |first6=Alfred H. |last7=Peacock |first7=Munro |last8=Miller |first8=Paul D. |last9=Lederman |first9=Samuel N. |journal=New England Journal of Medicine |volume=354 |issue=8 |pages=821–31 |pmid=16495394}}</ref><ref name="pmid18725648">{{cite journal |doi=10.1200/JCO.2008.16.3832 |title=Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer |year=2008 |last1=Ellis |first1=G. K. |last2=Bone |first2=H. G. |last3=Chlebowski |first3=R. |last4=Paul |first4=D. |last5=Spadafora |first5=S. |last6=Smith |first6=J. |last7=Fan |first7=M. |last8=Jun |first8=S. |journal=Journal of Clinical Oncology |volume=26 |issue=30 |pages=4875–82 |pmid=18725648}}</ref> Ovaj lek je razvilo biotehnološko preduzeće [[Amgen]].<ref>{{cite web|url=http://www.amgen.com/medpro/products_prolia.html|publisher=Amgen|accessdate=6. 5. 2012.|title=Prolia (denosumab)|work=Products|archive-date=2015-09-29|archive-url=https://web.archive.org/web/20150929025841/http://www.amgen.com/medpro/products_prolia.html|dead-url=yes}}</ref> Denosumab je IgG2 monoklonalno antitelo koje je inhibira [[RANKL]] ligand.<ref>Malan J, Ettinger K, Naumann E, Beirne OR: The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6. doi: 10.1016/j.oooo.2012.08.439. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/23159111 23159111]</ref><ref>{{Cite pmid|21059682}}</ref><ref>{{cite pmid|18048412}}</ref>

== Reference ==
{{reflist|2}}

== Literatura ==
{{refbegin}}
* {{cite news |first=Emily P. |last=Walker |date = 7. 2. 2012. |title=Benefit of Bone Drug in Prostate Cancer in Doubt |url=http://www.medpagetoday.com/HematologyOncology/ProstateCancer/31039 |work=MedPage Today}}
* {{GoodmanGilman10th}}
* {{FoyePrinciplesMedChem6th}}
{{refend}}
== Spoljašnje veze ==
{{Portal-lat|Medicina|Hemija}}
{{Commonscat-lat|Denosumab}}
* [http://www.drugbank.ca/drugs/DB06643 Denosumab]

{{Lekovi za tretman bolesti kostiju}}

[[Kategorija:Monoklonalna antitela]]